Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors

Front Immunol. 2022 Jun 16:13:941254. doi: 10.3389/fimmu.2022.941254. eCollection 2022.

¹ School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.
² School of Medicine, Washington University at St. Louis, St. Louis, MO, United States.
³ Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
⁴ Division of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology (IEO), Milan, Italy.
⁵ W Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, United States.
⁶ School of Life Sciences, Institute for Immunology, Ministry of Education (MOE) Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, China.
⁷ Tsinghua-Peking Center for Life Sciences, Beijing, China.

No abstract available

Keywords: PD-1/PD-L1; age and sex; age and sex-based different immune responses; anti-CTLA-4; cancer immunotherapy; immune checkpoint inhibitors.

Publication types